A federal advisory committee said Wednesday that there was adequate evidence that the drug Provenge prolongs the lives of men with advanced prostate cancer, an endorsement that makes it more likely that Medicare will pay for the $93,000 treatment.
The Medicare Coverage Advisory Committee voted that it had “intermediate confidence’’ in the strength of the data that the drug, developed by Dendreon, improves survival.
This is why health insurance can only get more expensive, at least so long as we want it to cover every kind of treatment.
- Who again is supposed to cut the rate of growth of Medicare spending? (marginalrevolution.com)